ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DEPO Depomed, Inc. (delisted)

7.30
0.00 (0.00%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Depomed, Inc. (delisted) NASDAQ:DEPO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.30 7.25 7.43 0 01:00:00

Depomed to Present at Healthcare Conferences in March

06/03/2018 9:04pm

GlobeNewswire Inc.


Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Depomed, Inc. (delisted) Charts.

Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of March.

30th Annual ROTH Capital Partners Conference

Date: Tuesday, March 13, 2018 Time: 12:30 p.m. PDT/ 3:30 p.m. EDT Location: Dana Point, California

Oppenheimer 27th Annual Healthcare Conference

Date: Tuesday, March 20, 2018 Time: 1:35 p.m. EDT Location: New York, New York

The fireside chats will be webcast live and may be accessed via the Investor Relations’ page of the Depomed website at www.depomed.com.  A recording of these events will be archived for 30 days on the company's website.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its neurology and pain franchises and its emerging specialty/orphan franchise is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com. 

Investor and Media Contacts:

Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 ckeenan@depomed.com

Dan Peisert VP, Business Development dpeisert@depomed.com

1 Year Depomed, Inc. (delisted) Chart

1 Year Depomed, Inc. (delisted) Chart

1 Month Depomed, Inc. (delisted) Chart

1 Month Depomed, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock